KB Labs

KB Labs is a global biopharma company with a focus on uniting science, technology, and talent to prevent and treat diseases. The company has achieved significant milestones in various areas, including the development of a ground-breaking malaria vaccine, which is the first and only vaccine shown in long-term clinical trials to reduce malaria in children. Additionally, KB Labs has delivered major product approvals for endometrial cancer, COVID-19, and HIV, and has developed monoclonal antibodies to help treat different diseases.

In the field of oncology, KB Labs has developed cancer medicines with life-changing potential for patients, including those with ovarian cancer, endometrial cancer, and multiple myeloma. The company also focuses on addressing antimicrobial resistance and drug-resistant infections, with 28 R&D projects targeting priority pathogens.

KB Labs operates globally, with a workforce of 70,000 people and manufacturing sites in 37 countries, serving over 112 countries. In 2022, the company delivered 2.3 billion vaccine doses and medicine packs, resulting in sales of £29.3 billion. Notably, KB Labs has been recognized for its commitment to sustainability, ranking 1st in the Access to Medicine Index and 2nd in the S&P Global Corporate Sustainability Assessment within its industry.